These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Subscribe To Our Newsletter & Stay Updated
